# Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis

> **NCT00418847** · PHASE2 · COMPLETED · sponsor: **The Hospital for Sick Children** · enrollment: 5 (actual)

## Conditions studied

- Gangliosidoses GM2

## Interventions

- **DRUG:** miglustat

## Key facts

- **NCT ID:** NCT00418847
- **Lead sponsor:** The Hospital for Sick Children
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2016-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418847, "Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00418847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*